165 related articles for article (PubMed ID: 38294686)
21. Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Yu G; Shen Y; Xu X; Zhong F
PLoS One; 2020; 15(11):e0242982. PubMed ID: 33253313
[TBL] [Abstract][Full Text] [Related]
22. Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) - A systematic review and meta-analysis.
Zer A; Prince RM; Amir E; Abdul Razak AR
Cancer Treat Rev; 2018 Feb; 63():71-78. PubMed ID: 29253836
[TBL] [Abstract][Full Text] [Related]
23. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J
Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918
[TBL] [Abstract][Full Text] [Related]
24. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.
Wu H; Huang N; Zhao C; Hu X; Da L; Huang W; Shen Y; Xiong F; Zhang C
Ann Transl Med; 2022 Mar; 10(6):294. PubMed ID: 35433955
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
[TBL] [Abstract][Full Text] [Related]
26. The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer.
Wang F; Jin F; Cheng B; Zhang Y; Zhou Q; Wang S
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1721-1735. PubMed ID: 34357411
[TBL] [Abstract][Full Text] [Related]
27. Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer.
Zhang C; Wang J; Wang X; Meng Z; Cheng Y; Li K
Cancer Biol Med; 2021 Jul; 19(8):1249-58. PubMed ID: 34302324
[TBL] [Abstract][Full Text] [Related]
28. [Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
Yan Q; Yao WT; Du XH; Guo LY; Fan YC
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):904-910. PubMed ID: 37875427
[No Abstract] [Full Text] [Related]
29. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S
Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536
[TBL] [Abstract][Full Text] [Related]
30. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
[TBL] [Abstract][Full Text] [Related]
31. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
[TBL] [Abstract][Full Text] [Related]
32. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Frezza AM; Assi T; Lo Vullo S; Ben-Ami E; Dufresne A; Yonemori K; Noguchi E; Siontis B; Ferraro R; Teterycz P; Duffaud F; Ravi V; Vincenzi B; Gelderblom H; Pantaleo MA; Baldi GG; Desar I; Fedenko A; Maki RG; Jones RL; Benjamin RS; Blay JY; Kawai A; Gounder M; Gronchi A; Le Cesne A; Mir O; Czarnecka AM; Schuetze S; Wagner AJ; Adam J; Barisella M; Sbaraglia M; Hornick JL; Meurgey A; Mariani L; Casali PG; Thornton K; Stacchiotti S
Cancer; 2020 Jan; 126(1):98-104. PubMed ID: 31536651
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.
Wang HY; Chu JF; Zhang P; Wang JQ; Yan Z; Yao SN; Yao ZH; Liu YY
Onco Targets Ther; 2020; 13():1561-1568. PubMed ID: 32110053
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in
He Z; Yang X; Ma T; Yang Q; Zhang C; Chen Y; Wang P; D'Incecco A; Metro G; Uematsu S; Wang Q
Transl Lung Cancer Res; 2022 Aug; 11(8):1657-1666. PubMed ID: 36090635
[TBL] [Abstract][Full Text] [Related]
35. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
[TBL] [Abstract][Full Text] [Related]
36. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
Li Y; Sun Z; Sun W; Wang H; Zu J
Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.
Liu Y; Xiao Q; He J; Hu H; Du J; Zhu Y; Chen J; Liu Z; Wang J; Sun L; Xu D; Li J; Liao X; Wang J; Cai Y; Cai C; Jin Z; Wang L; Yuan Y; Ding K
BMC Med; 2022 May; 20(1):155. PubMed ID: 35513832
[TBL] [Abstract][Full Text] [Related]
39. Implication of
Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
[No Abstract] [Full Text] [Related]
40. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
Front Oncol; 2022; 12():939343. PubMed ID: 35965587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
